Analysts: Genmab’s first major acquisition fits the strategy
With the addition of three new candidates in clinical development, Genmab is strengthening its portfolio.
by MARKETWIRE
Genmab’s acquisition of US-based Profoundbio fits well with the Danish biotech company’s strategy. The acquisition also gives Genmab access to a new technology and three candidates in clinical development that complement the existing portfolio, Søren Løntoft Hansen, Senior Analyst at financial institution Sydbank, told Marketwire.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
